Skip to content

Randomized controlled study on clinical efficacy and safety of total mesorectal excision (TaTME) through anus for low rectal cancer

Clinical efficacy and safety of total mesorectal excision (TaTME) through anus for low rectal cancer

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300078305
Enrollment
Unknown
Registered
2023-12-04
Start date
2019-09-01
Completion date
Unknown
Last updated
2023-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rectal cancer

Interventions

TaTME group:TaTME
LaTME group:LaTME

Sponsors

The First Affiliated Hospital of University of South China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Age range from 20 to 80 years old, regardless of gender; 2) Confirmed by histopathology as rectal adenocarcinoma; 3) The distance from the anal margin is 0-7cm; 4) Magnetic resonance imaging (MRI), ultrasound colonoscopy, computed tomography (CT), and other examinations did not detect distant metastasis, and the staging was T1-3N0M0; 5) Able to tolerate surgical treatment under general anesthesia, with ASA grading of I-III

Exclusion criteria

Exclusion criteria: 1) Previous history of other abdominal surgeries; 2) Recurrent rectal cancer patients; 3) T4 tumor or MRI showing positive CRM; 4) Invasion of the anal margin and other clear indications require combined abdominal and perineal resection (Miles); 5) Those who cannot adhere to follow-up or have poor compliance

Design outcomes

Primary

MeasureTime frame
3-year disease-free survival rate;3-year overall survival rate;

Secondary

MeasureTime frame
Positive rate of circumferential cutting edge;Integrity score of mesorectum;Collect the total number of lymph nodes;

Countries

China

Contacts

Public ContactJun Ouyang

The First Affiliated Hospital of University of South China

2018011970@usc.edu.cn+86 139 7342 6200

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026